JW Therapeutics Clarifies Carteyva Economics After NRDL Inclusion – Confirms RMB 288,600 Payment Standard and Projects Unit Production Cost Cuts Exceeding 65% from 2027

Fineline Cube
4 Min Read
Summarize with AI

JW Therapeutics (HKG: 2126) issued a statement clarifying inaccurate statements circulating online regarding the production costs and profitability of Carteyva (relmacabtagene autoleucel injection, relma‑cel) following its inclusion in China’s National Reimbursement Drug List (NRDL).

- Advertisement -

NRDL Pricing Snapshot

ItemDetail
CompanyJW Therapeutics (HKG: 2126)
ProductCarteyva (relmacabtagene autoleucel injection, relma‑cel), CAR‑T therapy
NRDL Payment StandardRMB 288,600
Effective Date1 January 2027
Pricing BasisComprehensive consideration of clinical value, patient accessibility, and sustainable business operations, reached after full communication with the National Healthcare Security Administration (NHSA)
Projected Cost ReductionUnit production cost to decrease by more than 65% from the actual 2025 level, starting in 2027

Company Clarification & Cost Outlook

  • Response to Online Claims: JW Therapeutics addressed circulating statements that directly compare historical production costs with the future NRDL payment standard to infer product profitability — noting such inferences fail to account for the continued decline in the company’s production costs.
  • Cost‑Reduction Drivers: The company expects the unit production cost of Carteyva to fall by more than 65% from the actual 2025 level starting in 2027, driven by (i) advancement of self‑supply of core raw materials such as lentiviral vectors, (ii) localization of certain raw materials and consumables, and (iii) continuous improvements in production efficiency.
  • Quality Commitment: JW Therapeutics pledged that cost reduction will always be premised on not compromising quality standards.
  • Manufacturing Reliability: The current one‑time preparation success rate for commercial production of Carteyva exceeds 99% — a key metric for autologous CAR‑T therapies, where manufacturing failure carries direct patient and revenue consequences.
  • Pricing Rationale: The RMB 288,600 NRDL payment standard, effective 1 January 2027, reflects a balance of clinical value, patient accessibility, and sustainable business operations negotiated with the NHSA.

Market Impact & Outlook

  • CAR‑T Access Landscape: With a sub‑RMB 300,000 reimbursement standard, Carteyva becomes markedly more accessible to Chinese patients — a milestone for CAR‑T affordability in a market where cell therapies have historically been priced beyond most patients’ reach.
  • Margin Narrative Correction: By publicly projecting a >65% unit cost reduction, JW Therapeutics is directly countering profitability concerns that the NRDL price would erode economics — framing the reimbursement price as sustainable given its cost trajectory.
  • Vertical Integration Edge: Self‑supply of lentiviral vectors and localization of consumables reduce dependence on imported materials, a structural cost and supply‑chain advantage increasingly decisive for commercial‑stage cell therapy companies in China.
  • Commercial Execution: The combination of NRDL reimbursement (from 1 Jan 2027), >99% manufacturing success, and declining unit costs positions Carteyva for volume‑driven commercial scaling; actual sales trajectory and patient uptake remain to be observed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Carteyva’s NRDL reimbursement implementation, projected production cost reductions, and commercial expectations. Actual results may differ materially due to risks including manufacturing scale‑up, raw‑material self‑supply execution, reimbursement administration at the provincial level, competitive CAR‑T therapies, and changes in China’s healthcare security policies. Cost‑reduction projections are management expectations and are not guaranteed.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *